
The third part of the guidelines of the Polish Psychiatric Association presents principles for the management of patients with schizophrenia and co-occurring substance use disorder (dual diagnosis). The authors emphasize that effective treatment requires an integrated care model led by a single multidisciplinary team, ensuring continuity of care, assessment of adherence to treatment recommendations, and consideration of psychosocial factors. A key element is relapse prevention through monitoring early warning signs, implementing individualized action plans, appropriate pharmacotherapy (including long-acting antipsychotics for patients with poor adherence), concurrent treatment of substance use disorder, and active family support. The guidelines also discuss management in specific situations, such as pregnancy, adolescence, advanced age, and comorbid somatic diseases, highlighting the need for individualized therapy and close collaboration among specialists. Treatment effectiveness should be assessed in a multidimensional manner ‒ through control of schizophrenia symptoms, reduction in substance use, and improvement in quality of life and social functioning. The document concludes with a set of practical recommendations covering diagnosis, pharmacotherapy, psychotherapy, safety monitoring, and strategies for harm reduction and relapse prevention.
This article provides an overview of international guidelines for the treatment of the cooccurrence of schizophrenia and substance use disorders (dual diagnosis, DD). The authors emphasize that the available guidelines recommend a comprehensive assessment of both disorders and integrated treatment; however, there is a lack of clear recommendations regarding the selection of antipsychotic medications. The choice of pharmacotherapy should take into account the symptom profile, the risk of interactions with psychoactive substances, safety, adverse effects, and adherence to treatment. For patients with low adherence, longacting antipsychotics (LAIs) are recommended, and cariprazine may be beneficial in patients with severe negative symptoms and substance craving. Addiction treatment should proceed in parallel with schizophrenia treatment and include both pharmacotherapy and psychosocial interventions. The integrated model, in which a single therapeutic team provides simultaneous treatment for both disorders, is considered the standard of care. Psychoeducation, motivational interviewing, cognitive-behavioral therapy, family support, and harm reduction programs play a key role. This approach increases treatment retention, improves functioning, and reduces the risk of psychosis relapse and substance use recurrence.
Autism spectrum disorder and bipolar affective disorder exhibit partial symptomatic overlap, which can complicate accurate diagnosis and delay the implementation of appropriate treatment. Increasing research also points to the potential comorbidity of both conditions, further complicating the clinical picture, diagnostics, and therapy planning. The aim of this narrative review is to examine the literature concerning the relationship between autism spectrum disorder and bipolar affective disorder, with particular emphasis on the hypothesis that autistic traits and their associated chronic functional impairments may heighten susceptibility to the development or more severe course of bipolar affective disorder. Epidemiological data, diagnostic challenges, selected neurobiological and genetic mechanisms, as well as practical implications for diagnosis, treatment, and environmental support are discussed. A review of the literature highlights the need for cautious differential diagnosis, longitudinal observation, and interdisciplinary collaboration in the care of individuals with comorbid autism spectrum disorder and bipolar affective disorder. A better understanding of the relationship between these conditions may facilitate earlier recognition of affective symptoms in individuals on the autism spectrum and support more appropriate clinical assessment and management planning.
Objectives The aim of this study was to examine the psychosexual functioning of transgender individuals in Poland, with particular attention to their sexual experiences, partner relationships, and sexual satisfaction in the context of the transition process. Methods The study involved 104 transgender individuals at various stages of transition. Data were collected using a proprietary questionnaire and the Sexual Satisfaction Questionnaire (SSQ). Results The results indicate a relationship between the stage of transition and the level of sexual activity, satisfaction with sexual life, and openness in intimate relationships. Individuals at later stages of transition more frequently reported positive sexual experiences, higher levels of body acceptance, and fewer concerns related to physical intimacy. No significant associations were observed between sociodemographic variables and the level of sexual satisfaction. Conclusions The findings indicate an association between the stage of the diagnostic and therapeutic process and selected aspects of sexual functioning among transgender individuals. The obtained results highlight the importance of incorporating psychosexual care into a comprehensive approach to the health of this group and point to the need for further research on transgender sexuality.
Aim. The present study analyzed the polymorphism of the dopamine receptor gene DRD4, which is widely described in the literature as being associated with sensation seeking. Gambling disorder (GD) shares similar biological mechanisms and symptoms with substance use disorders (SUD). Therefore, a behavioral addiction group was selected for this study. During the research and recruitment process, it was revealed that all individuals undergoing treatment for gambling addiction were also addicted to amphetamine, which aligns with the biological mechanism related to brain neurotransmission. Materials and methods. The study sample consisted of 307 male participants: 107 men diagnosed with both gambling and amphetamine addiction (study group), and 200 non-addicted men without psychiatric disorders, who served as the control group. Both groups underwent psychometric assessment using the State-TraitAnxiety Inventory (STAI) and the NEO Five-Factor Personality Inventory, and were evaluated by a board-certified psychiatrist. Genomic DNA was extracted from peripheral blood according to standard protocols. The DRD4 Ex3 polymorphism was genotyped using the PCR technique. Results. Among individuals with gambling and amphetamine addiction who showed higher scores on the trait scale of the STAI and higher levels of Neuroticism, the s/s polymorphism of the DRD4 Ex3 gene occurred significantly more frequently compared to the control group with s/s, l/l, and s/l polymorphisms. Similarly, in addicted individuals with higher trait STAI scores and higher Neuroticism levels, the s/l polymorphism of the DRD4 Ex3 gene was significantly more prevalent than in the control group with s/s polymorphism. These findings indicate that the s/s and s/l genotypes occurred significantly more frequently in men addicted to gambling and amphetamine than in the control group, which may suggest an association between these DRD4 Ex3 variants and susceptibility to addiction. Conclusions. The present study demonstrates that addictions should be analyzed through a multifactorial lens. A correlation was observed between the DRD4 polymorphism and personality traits associated with addiction.